BIBLIOGRAPHY

Journal/Book Section Editor


Text Books


Books for General Readership

Monographs


*RPW bibl*


RPW bibl


*RPW bibl*


*RPW bibl*


RPW bibl


258. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB,


290. Widmer AF, Wenzel RP, Trilla A, Bale MJ, Jones RN, Doebbeling BN. Outbreak of *Pseudomonas aeruginosa*


RPW bibl


*RPW bibl*


RPW bibl


390. Pfaller MA, Wenzel RP. The Epidemiology of Fungal Infections. (submitted)


404. Wenzel RP. Managed Health Care: Outcomes and Update. In: Remington J., ed. Current Clinical Topics in

*RPW bibl*


460. Wenzel, RP. Introduction to antifungal prophylaxis in the surgical intensive care unit. (in press)


491. Fulco P, Wenzel RP. Ramoplanin, a review (in press)

**Abstracts/Letters to the Editor**


RPW bibl


RPW bibl


44. Stillman RI, Donowitz LG, Wenzel RP. The emergence of *Staphylococcus epidermidis* as a hospital wide nosocomial bloodstream pathogen. 23rd Interscience Conference on Antimicrobial agents and Chemotherapy, Las Vegas, Nevada, October 24-26, 1983.


89. Martin MA, Pfaller MA, Wenzel RP. Comparative effect of alternative handwashing agents on nosocomial


105. Wenzel RP. The continuing contribution of staphylococci to hospital-acquired infection. Abstracts of Hospital

RPW bibl


121. Wenzel RP, Bone R, Fein A, Quenzer R, Schentag J, Gorrlick KJ, Wesel NI, Perl T. Results of a second double-


137. Thievent B, Pittet D, Wenzel RP, Li N, Auckenthaler R, Suter PM. Bedside assessment of independent predictors of
death from septicemia at three clinically relevant times in SICU patients. 32nd Interscience Conference on Anti-

138. Pittet D, Tarara D, Wenzel RP. Attributable mortality, overall costs, and excess length of stay from nosocomial
bloodstream infection in SICU patients. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
Anaheim, California, October 11-14, 1992.

139. Pittet D, Thievent B, Wenzel RP, Li N, Suter PM. Active comorbidities determine the prognosis of septicemia in
critically ill patients. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim,
California, October 11-14, 1992.

140. Widmer AF, Trilla A, Doebbeling BN, Bale MJ, Wenzel RP, Jones RN. P aeruginosa outbreak in a SICU:
transmission by hands of a health care worker. 32nd Interscience Conference on Antimicrobial Agents and
Chemotherapy. Anaheim, California, October 11-14, 1992.

141. Doebbeling BN, Hollis RJ, Wenzel RP, Pfaller MA, Reagan DR. Prospective evaluation of Candida hand carriage:
molecular typing of paired isolates. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
Anaheim, California, October 11-14, 1992.

32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, California, October 11-14,

143. Doebbeling B, Breneman D, Marsh R, Reagan D, Wenzel R. Multi-center study of elimination of Staphyl-
ococcus aureus nasal carriage with calcium mupirocin ointment in health subjects. 32nd Interscience Conference on

MAb Study Group. Monoclonal antibody to human tumor necrosis factor (TNF MAb): multi-center efficacy and
safety study in patients with the sepsis syndrome. 33rd Interscience Conference on Antimicrobial Agents and

marker for nosocomial infections. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New

146. Voss A, Hollis R, Wenzel RP, Doebbeling BN. Investigation of the sequence of colonization and candidemia in
nonimmunocompromised patients. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New

147. Hollis RJ, Barr J, Wenzel RP. Familial carriage of methicillin-resistant Staphylococcus aureus and subsequent
infection in a newborn sibling. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New

antibody. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana,
October 16-20, 1993.

149. Pittet D. Rangel-Frausto S, Tarara D, Costigan M, Wenzel RP. SIRS, sepsis, and severe sepsis: incidence,
morbidities, and outcome in SICU patients. 33rd Interscience Conference on Antimicrobial Agents and

150. Edmond MB, Hollis RJ, Houston AK, Wenzel RP. Epidemiologic analysis of an outbreak of meningococcal
disease. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana,
October 16-20, 1993.

151. Rangel-Frausto MS, Martin MA, Saiman L, Blumberg H, Patterson JE, Pfaller MA, Wenzel RP, the NEMIS Study

RPW bibl


RPW bibl


203. Wenzel RP. Why Does Therapy Fail (Or Appear to Succeed)? 42nd ICAAC Abstracts; #38(L,K)-413, p.450, 2002.


RESEARCH SUPPORT SUMMARY

**University of Virginia 1972-1986**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th># Years of Funding</th>
<th>Project</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institutes of Health</td>
<td>1974-78</td>
<td>Study of the Efficacy of an OSU-1 Mycoplasma pneumoniae Vaccine in Marine Corps Recruits</td>
</tr>
<tr>
<td>Centers for Disease Control</td>
<td>1974-78</td>
<td>Development of a Statewide Program for Surveillance/Control of Nosocomial Infections</td>
</tr>
<tr>
<td>State of Virginia</td>
<td>1978-84</td>
<td>Continuation of CDC Project to Develop Statewide Program for Surveillance and Control of Nosocomial Infections</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>1985-86</td>
<td>Analysis of Attributable Mortality Data in Nosocomial Pneumonia - Fogerty Award</td>
</tr>
</tbody>
</table>

**University of Iowa 1986-1995**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Period</th>
<th>Project</th>
</tr>
</thead>
</table>
| Cutter Biological        | 3/87-3/88 | Efficacy of Pseudomonas Immune Globulin in the Treatment of P aeruginosa Bacteremia in Compromised Patients | $5,000
<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Period</th>
<th>Project</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xoma Corporation</td>
<td>3/87-4/89</td>
<td>Efficacy of Anti-Endotoxin Antibody in the Treatment of Suspected Gram-Negative Sepsis</td>
<td>$94,800</td>
</tr>
<tr>
<td>Glaxo, Inc.</td>
<td>8/87-8/88</td>
<td>Comparison of Cefzolin to Cefuroxime in Cardiac Surgery</td>
<td>$10,000</td>
</tr>
<tr>
<td>Roerig/Pfizer</td>
<td>8/87-12/88</td>
<td>In Vitro Susceptibility of Unique Nosocomial Bloodstream Isolates to new Antibiotics</td>
<td>$18,095</td>
</tr>
<tr>
<td>Hoechst-Roussel</td>
<td>1/88-7/88</td>
<td>Effects of Protein Binding on In Vitro Susceptibility of Unique Nosocomial Bloodstream Isolates</td>
<td>$22,000</td>
</tr>
<tr>
<td>Lederle Laboratories</td>
<td>8/88-7/89</td>
<td>Comparison of Beta-Lactam Antibiotics Plus Gentamycin-Bloodstream Isolates</td>
<td>$8,500</td>
</tr>
<tr>
<td>Calgon Vestal</td>
<td>7/87-6/90</td>
<td>Efficacy Study of Handwashing Agents: Calstat vs. Hibiclens</td>
<td>$68,000</td>
</tr>
<tr>
<td>ER Squibb and Sons</td>
<td>8/87-7/89</td>
<td>Attributable Mortality of Hospital</td>
<td>$20,000</td>
</tr>
<tr>
<td>Xoma Corporation</td>
<td>5/89-11/91</td>
<td>Efficacy of Anti-Endotoxin Antibody in the Treatment of Suspected Gram-Negative Sepsis</td>
<td>$157,400</td>
</tr>
<tr>
<td>Beecham</td>
<td>6/89-6/90</td>
<td>Efficacy of Mupirocin Ointment for the Eradication of Nasal Mucosa Carriage of Staphylococcus aureus</td>
<td>$53,000</td>
</tr>
<tr>
<td>Lilly Laboratories</td>
<td>11/89-11/90</td>
<td>Cilofungin in Disseminated Candidiasis: Dose Ranging Study</td>
<td>$21,605</td>
</tr>
<tr>
<td>Fujisawa SmithKline Corporation</td>
<td>1/90-12/90</td>
<td>In Vitro Susceptibility of Unique Nosocomial Bloodstream Isolates to New Antibiotics</td>
<td>$9,750</td>
</tr>
<tr>
<td>Hoechst-Roussel</td>
<td>6/90-5/91</td>
<td>Use of Pentoxifylline (Trental) in Patients with Amphoteresin B Induced Renal Toxicity - Pilot Study</td>
<td>$11,500</td>
</tr>
<tr>
<td>Pfizer</td>
<td>12/90-7/92</td>
<td>Risk Factors Associated with</td>
<td>$44,825</td>
</tr>
<tr>
<td>Sponsor</td>
<td>Period</td>
<td>Project</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Pharmaco/Synergen</td>
<td>4/91-8/92</td>
<td>Human Recombinant Interleukin-1 Receptor Antagonist (IL-Irs) in the Treatment of Sepsis Syndrome</td>
<td>Cutter (Miles)</td>
</tr>
<tr>
<td>Kimberly Clark</td>
<td>8/91-1/92</td>
<td>Sterile Wrap Events Study (Pilot Phase)</td>
<td>Pfizer Roerig</td>
</tr>
<tr>
<td>Pharmaco/Synergen</td>
<td>7/92-6/93</td>
<td>A Study to Evaluate the Safety and Efficacy of Human Recombination Interleukin-1 Receptor Antagonist (IL-IRA) in the Treatment of Sepsis Syndrome</td>
<td></td>
</tr>
<tr>
<td>Kimberly Clark</td>
<td>7/92-2/93</td>
<td>Sterile Wrap Study</td>
<td>Kimberly Clark</td>
</tr>
<tr>
<td>Pact</td>
<td>7/93-6/94</td>
<td>Sterile Wrap Events Study</td>
<td>Kimberly Clark</td>
</tr>
<tr>
<td>National Institutes of Health</td>
<td>9/91-8/96</td>
<td>Research Training Grant in Hospital Epidemiology (T-32)</td>
<td>Merck</td>
</tr>
<tr>
<td>Miles</td>
<td>5/94-2/95</td>
<td>Multicenter Study to Compare the Safety, Tolerability and Immunogenicity of Three Consistency Lots of VAQTA in Healthy Adults</td>
<td></td>
</tr>
</tbody>
</table>

RPW bibl
<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Period</th>
<th>Project</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott</td>
<td>9/94-9/95</td>
<td>Achievement Awards Outcomes Research</td>
</tr>
<tr>
<td>Lederle Laboratories</td>
<td>9/94-9/95</td>
<td>SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance</td>
</tr>
<tr>
<td>SmithKline-Beecham</td>
<td>Period 9/94-9/95</td>
<td>Project A Randomized Placebo-Controlled, Double-Blind Comparative Study of Intranasal Mupirocin Ointment for Preventing <em>S. aureus</em> Surgical Wound Infections</td>
</tr>
<tr>
<td>Rhone-Poulenc</td>
<td>1997-2001</td>
<td>SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance</td>
</tr>
<tr>
<td>Pfizer Inc</td>
<td>1997-2002</td>
<td>SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance</td>
</tr>
<tr>
<td>Proctor and Gamble</td>
<td>1997-1998</td>
<td>Handwashing and Predictors of Compliance</td>
</tr>
<tr>
<td>Rhone-Poulenc</td>
<td>1998</td>
<td>Educational Conference - SCOPE</td>
</tr>
<tr>
<td>Merck</td>
<td>1999-2002</td>
<td>SCOPE: Pharmacy Component</td>
</tr>
<tr>
<td>Intrabiotics</td>
<td>1998-2000</td>
<td>Ramoplanin for VRE GI decolonization</td>
</tr>
<tr>
<td>Pharmacia and Upjohn</td>
<td>2000-2002</td>
<td>Antibiotic resistance in the community</td>
</tr>
<tr>
<td>Pfizer</td>
<td>2002-2003</td>
<td>SCOPE</td>
</tr>
<tr>
<td>Cubist</td>
<td>2003</td>
<td>SCOPE</td>
</tr>
<tr>
<td>Pfizer</td>
<td>2003-2006</td>
<td>SCOPE</td>
</tr>
</tbody>
</table>

1995 -
*Medical College of Virginia/Virginia Commonwealth University*

- Lederle Laboratories: 9/95-12/96, SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance, $150,000
- Rhone-Poulenc: 1997-2001, SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance, $205,000
- Pfizer Inc: 1997-2002, SCOPE: Surveillance and Control Pathogens of Epidemiologic Importance, $790,000
- Proctor and Gamble: 1997-1998, Handwashing and Predictors of Compliance, $74,000
- Rhone-Poulenc: 1998, Educational Conference - SCOPE, $250,000
- Merck: 1999-2002, SCOPE: Pharmacy Component, $300,000
- Intrabiotics: 1998-2000, Ramoplanin for VRE GI decolonization, $85,000
- Pharmacia and Upjohn: 2000-2002, Antibiotic resistance in the community, $400,000
- Pfizer: 2002-2003, SCOPE, $200,000
- Cubist: 2003, SCOPE, $5,000
- Pfizer: 2003-2006, SCOPE, $200,000

*RPW bibl*